Alterity Therapeutics Limited
ATHE · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 35.3% | 2.6% | -23.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 97.7% | 94.7% | 92.7% | 92.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -269% | -486.9% | -372.8% | -339.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -223.4% | -475.8% | -352.5% | -250.7% |
| EPS Diluted | -1.14 | -3.12 | -3.42 | -3.18 |
| % Growth | 63.5% | 8.8% | -7.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |